AA560 is an orally active nonsteroidal antiandrogen (NSAA) that was developed in Japan and was first described in the literature in 1977 but was never marketed.[1][2][3] It is an anilide derivative and analogue of the NSAA flutamide, and shows greater in vivo antiandrogenic potency than does flutamide.[1][2] Similarly to flutamide, AA560 is a selective antagonist of the androgen receptor (AR) and consequently shows progonadotropic effects by increasing levels of gonadotropins and testosterone via disinhibition of the hypothalamic-pituitary-gonadal axis.[1][2][4]
Clinical data | |
---|---|
Other names | AA-560; N-(2-Chloromethyl-2-hydroxypropionyl)-3,4,5-trichloroaniline |
Routes of administration | By mouth[1] |
Drug class | Nonsteroidal antiandrogen |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C10H10Cl3NO2 |
Molar mass | 282.55 g·mol−1 |
3D model (JSmol) |
|
| |
|